Evaluation of pharmacotherapy with perindopril, losartan potassium, and their combination in elderly patients with chronic heart failure

Abstract

Seventy-eight patients with chronic heart failure (CHF) FC II–IV (according to the NYHA classification), which complicated the course of coronary heart disease (CHD) at the left ventricular ejection fraction (LVEF) ≤45% were examined in order to evaluate the effects of pharmacotherapy with perindopril, losartan potassium, and their combination on the severity of clinical symptoms, hemodynamics, tolerance to physical activity, and the morphofunctional parameters of the heart in elderly patients with CHF. The study included 42 men (53.8%) and 36 women (46.2%) at the average age of 64.8 ± 3.7 years. It was found that under long-term monotherapy with perindopril or losartan potassium the CHF FC was significantly reduced and the LVEF was significantly increased (p < 0.05) in patients with CHF complicating the course of CHD. At the same time, there were no advantages of combined treatment with perindopril and losartan potassium over monotherapy. A significant decrease in the frequency of angina attacks, viz., by 28.5 and 27%, respectively (p < 0.05), was observed in these patients only after long-term treatment with perindopril and the combination of perindopril and losartan potassium.